Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Evo 2 represents a cutting-edge genomic foundation model that excels in making predictions and designing tasks related to DNA, RNA, and proteins. It employs an advanced deep learning architecture that allows for the modeling of biological sequences with single-nucleotide accuracy, achieving impressive scaling of both compute and memory resources as the context length increases. With a robust training of 40 billion parameters and a context length of 1 megabase, Evo 2 has analyzed over 9 trillion nucleotides sourced from a variety of eukaryotic and prokaryotic genomes. This extensive dataset facilitates Evo 2's ability to conduct zero-shot function predictions across various biological types, including DNA, RNA, and proteins, while also being capable of generating innovative sequences that maintain a plausible genomic structure. The model's versatility has been showcased through its effectiveness in designing operational CRISPR systems and in the identification of mutations that could lead to diseases in human genes. Furthermore, Evo 2 is available to the public on Arc's GitHub repository, and it is also incorporated into the NVIDIA BioNeMo framework, enhancing its accessibility for researchers and developers alike. Its integration into existing platforms signifies a major step forward for genomic modeling and analysis.
Description
Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.
API Access
Has API
API Access
Has API
Integrations
Evo Designer
GitHub
Google Cloud Platform
Hugging Face
NVIDIA BioNeMo
Integrations
Evo Designer
GitHub
Google Cloud Platform
Hugging Face
NVIDIA BioNeMo
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Arc Institute
Country
United States
Website
arcinstitute.org/tools/evo
Vendor Details
Company Name
Genomenon
Country
United States
Website
www.genomenon.com/pharma/